Chemoradiation Clinical Trial
Official title:
PRIME - Pre Radiotherapy Daily Exercise Training in Non-Small Cell Lung Cancer
The aim of this study is to evaluate the feasibility and the effect of daily, individual, supervised and structured exercise training before radiotherapy in patients diagnosed with Non-Small Cell Lung Cancer. Primary outcome is maximal oxygen uptake (VO2peak). The hypotheses are that patients who undergo daily exercise training will increase VO2peak, functional capacity (measured by 6-minute walk test (6MWD)) and lung function (forced expired volume in one second (FEV1)).
Pre intervention screening: Each patient was screened by a clinical nurse specialist prior to participating in the study. Before baseline and post test the patient was screened by a research physiotherapist and/or human physiology students. If one of the following criteria were met, the patient was prohibited from being tested on that day: diastolic blood pressure <45 or >95, heart rate (HR) at rest >115/min, temperature > 38 0C, respiratory rate at rest >30/min, infection requiring treatment, fresh bleeding, total leucocyte count <1.0 109/L or platelets <50 109/L. Control - Usual care: The patients randomized to the control group received no training but conducted baseline and post test (6MWD, spirometry, VO2peak and questionnaires) just as the intervention group. Furthermore, patients in control were equipped with a Garmin vivo-smart HR® activity tracker every day in 24h during the course of radiotherapy treatment. Intervention - The patients randomized to the intervention group received daily training and conducted baseline and post test (6MWD, spirometry, VO2peak and questionnaires). Furthermore, patients were equipped with a Garmin vivo-smart HR® activity tracker every day in 24h during the course of radiotherapy treatment. The supervised daily training was carried out individually and each session had a duration of 20 minutes before patients individual prescribed radiotherapy. Training was conducted at National Hospital of Denmark: Department of Radiation Oncology , section 3981, entry 39. supervised by a research physiotherapist and/or human physiology students. Statistical analysis sample size: According to the sample size the calculation is performed on the basis of alteration in VO2peak from the study "EXHALE" (55 patients who completed a 6 weeks training period). The calculation is based on an increase of 200 ml/min in VO2peak for patients in the intervention group (SD = 2,48) and it is assumed that the patients in the control group will have a reduction of 100 ml/min (SD = 2,48). Assumptions for calculation of patient numbers are as follows: Type 1 error 0.05, type 2 error 0.20, SD 2.48. This leads to a total number of 24 patients (12 in each arm). A drop-out rate of 40% is included. Therefore another 16 patients is added, which gives a sample size of 40 patients (20 in each arm). Data entry is carried out in the Open Clinica and data analyses will be performed using the computer programs R-Studio/R and SPSS. Data from questionnaires will be analyzed by SPSS. All other data will be analyzed by R. Differences between groups will be analyzed by an unparried t-test whereas differences within groups will be analyzed by a parried t-test. All categorical data are analyzed using the Pearson χ2 tests. Other data (e.g., from questionnaires) are analyzed using logistic regression and chi square or Mantel Haenzel test. Significance level is set at 0.05. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02677311 -
GnRHA Therapy and Ovarian Preservation in Pediatric Cancer Patient
|
N/A | |
Recruiting |
NCT03731130 -
Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant Radiation or Chemoradiation Followed by Surgery in Patients With Rectal Cancer
|
||
Completed |
NCT02979691 -
Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02969473 -
Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT01381913 -
Feasibility Trial of Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer
|
N/A | |
Recruiting |
NCT03712774 -
Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant or Definitive Chemoradiation in Patients With Esophageal Cancer
|
||
Terminated |
NCT03170115 -
Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer
|
Phase 2 | |
Recruiting |
NCT02979795 -
Translational Research in Identifying Molecular Mechanisms for Rectal Cancer Metastasis
|
N/A | |
Recruiting |
NCT05394415 -
Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC
|
Phase 1/Phase 2 | |
Recruiting |
NCT03427684 -
Study of Hypo-fractionated Neoadjuvant Radiotherapy for Locally Advanced Gastric Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03923309 -
Oncologic Risk of Rectal Preservation Against Medical Advice After Chemoradiotherapy for Rectal Cancer
|
||
Active, not recruiting |
NCT03475186 -
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
|
Phase 2 | |
Recruiting |
NCT03623737 -
Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC
|
Phase 2/Phase 3 | |
Completed |
NCT02966769 -
N2 Lung Cancer Project: Neoadjuvant Treatment Followed Surgery Versus Chemoradiation
|
N/A | |
Completed |
NCT02813967 -
S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer
|
Phase 3 | |
Completed |
NCT03298204 -
Definitive (Chemo)Radiotherapy for Patients With Esophageal Cancer - 3JECROG R-01
|
||
Completed |
NCT03461341 -
European iNvestigation of SUrveillance After Resection for Esophageal Cancer
|
||
Completed |
NCT03021668 -
Comparison Between Wound Vacuum Dressing and Standard Closure to Reduce Rates of Surgical Site Infections
|
N/A | |
Recruiting |
NCT02938195 -
Phase II Study of Neo-adjuvant Chemoradiotherapy for Squamous Cell Esophageal Cancer
|
Phase 2 | |
Recruiting |
NCT03225300 -
Simultaneous Integrated Boost in Malignant Glioma Patients Treated With Chemoradiation
|
N/A |